|
|
|
| Meta-Analysis of the Efficacy of Long-term Albumin Infusion for Patients with Cirrhosis and Ascites |
| CHEN Li, TAN Bo-yu, WEI Hong-yan, et al |
| Department of Pharmacology,People's Hospital of Hunan Province,410005,Changsha,Hunan |
|
|
|
|
Abstract 【Objective】 The clinical efficacy and safety of human serum albumin for patients with cirrhosis and ascites were systematically assessed. 【Methods】 We searched Medline,Embase,Cochrane Library,Pubmed,China Biomedical Literature (CBM),WanFang Datebase,VIP and Chinese Journal Full-text database (CNKI). The search deadline from above databases was May 2018. A randomized controlled trial of long-term infusion of human albumin combined with diuretics (the experimental group) and separate diuretics (the control group) in patients with cirrhosis and ascites was performed. Two reviewers were independently involved in the studies using RevMan5.2 software, performed quality assessment, extracted the data, evaluated the risk of bias, and made the conclusions. 【Results】 A total of 803 patients with 5 articles were included. Meta-analysis showed that the overall survival rate was improved in the experimental group compared with the control group [HR=0.60,95%CI(0.44,0.83),P=0.002]. Data also showed the experimental group significantly reduced the incidence of complications [RR=0.35,95%CI(0.18,0.69),P=0.002], re-admission rate [RR=0.23,95%CI(0.13,0.43),P<0.001] and ascites recurrence rate [RR=0.17,95%CI(0.07,0.42),P<0.001]. There were no significant differences between the two groups in the incidence of serious adverse reactions and human serum albumin related adverse events. 【Conclusion】 Long-term infusion of human serum albumin for patients with cirrhosis and ascites can increase the overall survival and reduce the incidence of complications and re-admissions. It does not increase the incidence of adverse reactions.
|
|
Received: 19 August 2018
|
|
|
|
|
|
[1] 李慧博,翟所迪.白蛋白在肝硬化及其并发症中的临床应用[J].临床药物治疗杂志,2018,16(1):32-37.
[2] Bernardi M, Ricci CS, Zaccherini G. Role of human albumin in the management of complications of liver cirrhosis[J].J Clin Exp Hepatol,2014, 4(4): 302-311.
[3] 陈丽.人血白蛋白在肝硬化腹水患者中的系统评价[D].湖南:湖南师范大学, 2014.
[4] Finfer S, Bellomo R, Boyce N,et al. A comparison of albumin and saline for fluid resuscitation in the intensive care unit [J].N Engl J Med,2004,350(22): 2247-2256.
[5] Wilkinson P, Sherlock S. The effect of repeated albumin infusions in patients with cirrhosis[J].Lancet,1962,280(7266):1125-1129.
[6] Gentilini P, Casini-Raggi V , Fiore G D, et al. Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial[J].J Hepatol,1999, 30(4):639-645.
[7] Vizzutti F, Romanelli R G , Raggi V C, et al. Diuretic and natriuretic effects of long-term albumin infusion in patients with cirrhosis and ascites[J].J Hepatol,2001,34(sl1): 17.
[8] Romanelli R G, Villa G, Barletta G, et al. Long-term albumin infusion improves survival in patients with cirrhosis and ascites: an unblinded randomized trial[J].World J Gastroenterol,2006,12(9): 1403-1407.
[9] Caraceni P, Riggio O, Angeli P, et al. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial[J].Lancet,2018,391(10137):1-13.
[10] Garcia-Tsao G. Long-term albumin in cirrhosis: is it the answer[J].Lancet,2018, 391(10138): 2391-2392. |
| [1] |
. [J]. JOURNAL OF CLINICAL RESEARCH, 2018, 35(8): 1575-1577. |
|
|
|
|
2018, Vol. 35 
